Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I 2: Investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 2, 2004, Pages 642-647

  Warner, Timothy D ^a   Vojnovic, Ivana ^a   Giuliano, Francesco ^a   Jiménez, Rosario ^a   Bishop Bailey, David ^a   Mitchell, Jane A ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE 3; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; BLOOD; BRAIN; CEREBELLUM; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; HEART; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACETAMINOPHEN; ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 3342945057     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.063875     Document Type: Article

References (23)

1. Bishop-Bailey D, Larkin SW, Warner TD, Chen G, and Mitchell JA (1997) Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture. Br J Pharmacol 121:125-133.
2. Bishop-Bailey D, Pepper JR, Larkin SW, and Mitchell JA (1998) Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids. Arterioscler Thromb Vasc Biol 18:1655-1661.
3. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, and Simmons DL (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci USA 99:13926-13931.
4. Dinchuk JE, Liu RQ, and Trzaskos JM (2003) COX-3: in the wrong frame in mind. Immunol Lett 86:121.
5. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, and Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063-1073.
6. Fitzgerald GA and Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433-442.
7. Giuliano F, Vojnovic I, and Warner TD (2002) Prostacyclin production from intact rat blood vessels is via the activity of cyclooxygenase-1 as defined by naproxen, paracetamol, rofecoxib and SC560. Br J Pharmacol 135:297P.
8. Green K, Drvota V, and Vesterqvist O (1989) Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins 37:311-315.
9. Kis B, Snipes JA, Isse T, Nagy K, and Busija DW (2003) Putative cyclooxygenase-3 expression in rat brain cells. J Cereb Blood Flow Metab 23:1287-1292.
10. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, and Fitzgerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272-277.
11. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, and Vane JR (1993) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693-11697.
12. Mitchell JA and Warner TD (1999) Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 128:1121-1132.
13. Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, et al. (1999) The discovery of rofecoxib [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)- furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 9:1773-1778.
14. Prescott LF (2000) Paracetamol: past, present and future. Am J Ther 7:143-147.
15. Sciulli MG, Seta F, Tacconelli S, Capone ML, Ricciotti E, Pistritto G, and Patrignani P (2003) Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. Br J Pharmacol 138:634-641.
16. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, and Isakson PC (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95:13313-13318.
17. Smith WL, DeWitt DL, and Garavito RM (2000) Cyclooxygenases: structural, cellular and molecular biology. Annu Rev Biochem 69:145-182.
18. Stanford SJ, Pepper JR, and Mitchell JA (2000) Cyclooxygenase-2 regulates granulocyte-macrophage colony-stimulating factor, but not interleukin-8, production by human vascular cells: role of cAMP. Arterioscler Thromb Vasc Biol 20:677-682.
19. Vane JR, Bakhle YS, and Botting RM (1998) Cyclooxygenase 1 and 2. Ann Rev Pharmacol Toxicol 38:97-120.
20. 2online 1:144.
21. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, and Vane JR (1999) Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568.
22. Warner TD and Mitchell JA (2002) Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci USA 99:13371-13373.
23. Warner TD and Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18:790-804.